June 14, 2018 @ 6:43 pm | Breaking News, Jubak Picks Portfolio |
Frankly, my holdings of shares and options on Nektar Therapeutics (NKTR) are driving me nuts. The stock is just so volatile that I can barely stand it even though I’m comfortable with the long-term trajectory of the company’s new non-addictive opioid and...
February 14, 2018 @ 6:55 pm | Breaking News, Jubak Picks Portfolio, NKTR, Update |
In the deal announced today Bristol-Myers Squibb (BMY) pays Nektar Therapeutics $1 billion upfront, $850 million for stock valued at a price of $102 a share, and a potential $1.78 billlion in milestone payments in exchange for access to NKTR 214, a drug candidate...
December 19, 2017 @ 6:51 pm | Breaking News, Jubak Picks Portfolio, NKTR |
No point in hoping that Nektar Therapeutics (NKTR) will match this year’s gain of 364% as of the close on December 18. But I think the stock could easily climb another 30% or more in 2018 as the company de-risks its very promising drug candidates in the opioid...